VolitionRx Earnings Call: Breakthroughs Amid Funding Strain

VolitionRX Ltd. ((VNRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

VolitionRx’s latest earnings call painted a picture of a company making meaningful scientific and commercial strides while still grappling with early‑stage scale and funding pressures. Management struck an optimistic tone around breakthrough data, new partnerships, and cost control, but acknowledged that revenues remain modest, volatile, and highly dependent on successful execution over the next few years.

Revenue Growth From a Small Base

VolitionRx reported full‑year 2025 revenue of $1.7 million, a 40% increase year over year, underscoring rapid percentage growth from a low base. Fourth‑quarter revenue surged 133% versus the prior year, supported by the first sales of its CE‑marked Nu.Q NETs product in Europe and early traction in key markets.

Cost Discipline Eases the Cash Burn

Operating expenses fell by $4.8 million in 2025, a 17% decline compared with 2024, reflecting disciplined cost controls. Net cash used in operating activities improved to $19.7 million, down 24% from $25.9 million, and management is targeting a further 25% to 30% reduction in cash operating expenses during 2026.

Financing Moves Shore Up Liquidity

The company ended the year with roughly $1.1 million in cash and cash equivalents, a low buffer given its cash burn but partially offset by post‑year‑end financings. By March 25, VolitionRx had raised about $5.4 million via its at‑the‑market facility, $1.9 million from a convertible note, and announced about $2.3 million in new nondilutive funding.

French‑Backed Sepsis Program Validates Nu.Q NETs

Nu.Q NETs (H3.1) was selected as the sole biomarker in the DETECSEPS program, a real‑world interventional sepsis detection study supported by the French government and budgeted at about $7.3 million. This moves the assay beyond research into interventional clinical use, potentially setting the stage for broader adoption if outcomes are favorable.

Growing Clinical and Peer‑Reviewed Validation

Multiple independent and peer‑reviewed studies reinforced the clinical potential of VolitionRx’s nucleosome‑based assays, particularly for critical care. Large studies at UMC Amsterdam and Jena covering more than 2,600 intensive care patients showed H3.1 can distinguish sepsis from noninfectious inflammation and outperformed standard scores such as APACHE II and SOFA, while Mayo Clinic data linked elevated nucleosomes to trauma complications.

Capture‑Seq Delivers Early‑Stage Cancer Breakthrough

The company highlighted a key scientific advance with its Nu.Q Capture‑Seq platform, which generated circulating tumor DNA sets with more than 99% purity. In a blinded validation cohort of 81 subjects, the test detected over 95% of stage 1 and 2 colorectal and lung cancers, signaling strong early‑stage detection potential and sparking growing interest among prospective partners.

Partnerships Expand Commercial Footprint

VolitionRx continued to broaden its commercial reach via multiple licensing and co‑marketing deals across its human health franchises. Agreements with Werfen, Hologic, and Revvity/PerkinElmer, alongside its Nu.Q Discover service now used by around 100 clients including leading pharmaceutical and diagnostic companies, point to a partner‑driven model that also includes active talks with roughly 10 major diagnostic and liquid biopsy players.

Veterinary Segment Builds Scale and Automation

The Nu.Q Vet Cancer Test has emerged as the leading canine cancer screening blood test in more than 20 countries, underscoring VolitionRx’s early leadership in the veterinary space. Fujifilm Vet Systems extended its contract to roll out a centralized automated platform, and the completion of chemiluminescent immunoassay validation in Japan should enable higher‑throughput, fully automated vet testing.

Feline Assay Opens New Market and Milestone

A clinical study showed the Nu.Q Vet feline assay detected more than 80% of feline lymphomas at 100% specificity, opening a new species segment for the company. Management expects that a forthcoming peer‑reviewed publication will trigger a $5 million milestone payment and help unlock a significant opportunity in the sizable U.S. cat population.

Point‑of‑Care Lateral Flow Progress

VolitionRx advanced its point‑of‑care ambitions by demonstrating that nucleosome levels can be measured via lateral flow from whole blood within minutes. A second research phase comparing whole blood and capillary samples in critically ill patients is underway, supporting the longer‑term vision of deploying low‑cost tests in resource‑constrained or bedside settings.

Early Commercial Stage and Revenue Volatility

Management repeatedly stressed that VolitionRx remains at an early commercialization phase, with quarterly revenue described as “fairly lumpy” and hard to forecast. Given uncertainty around the timing of new launches, partner ramp‑ups, and reimbursement decisions, the company declined to offer formal revenue guidance for 2026.

Scale Constraints From Small Revenue Base

Despite the impressive growth rates, the company’s $1.7 million in 2025 sales underscores that recurring revenues are still nascent and commercial scale is not yet reached. Investors are likely to focus on how quickly these early wins translate into stable, high‑margin revenue streams as more tests transition from research to routine clinical use.

Cash Burn and Funding Needs Remain Material

The improved but still substantial $19.7 million operating cash outflow and low year‑end cash position highlight ongoing funding risk, even after recent financings. VolitionRx’s runway will depend on further licensing deals, milestone receipts, and possibly additional capital raises, making execution on its partnership strategy critical for investors tracking dilution and liquidity.

Reliance on Partners and Long Timelines

Growth in both human diagnostics and veterinary markets hinges heavily on the adoption pace of partners implementing central lab automation and securing reimbursement. Key inflection points such as anticipated French reimbursement for Nu.Q Cancer in late 2026 could be pivotal, but also mean that more meaningful routine clinical revenue may not materialize during 2026.

Uncertain Economics of Capture‑Seq

While Capture‑Seq performance data are compelling, management acknowledged that the process currently requires a capture immunoassay step plus sequencing, driving up costs relative to simple immunoassays. With capture expenses cited in the tens of dollars and sequencing potentially a few hundred dollars, real‑world pricing and market acceptance will need to be tested as the platform moves closer to commercialization.

Need for Larger Validation and Automation

The promising Capture‑Seq results to date are based on relatively small cohorts such as the 81‑subject blinded validation study, underscoring the need for larger, multicenter trials. In addition, the workflow remains manual for now, and while management believes it is amenable to automation, broader rollout will require substantial integration work with lab and diagnostic partners.

Guidance and Near‑Term Expectations

Management refrained from providing specific revenue guidance for 2026 but outlined several operational priorities and milestones, including continuing to sign new licensing agreements with leading diagnostics firms and collecting a $5 million veterinary milestone this year. The company also aims to further reduce cash operating expenses by roughly 25% to 30%, pursue reimbursement and routine clinical adoption of Nu.Q Cancer in France by late 2026, and keep building on more than $25 million of nondilutive support secured to date.

VolitionRx’s earnings call underscored a classic high‑risk, high‑reward profile, with cutting‑edge nucleosome science and expanding partnerships set against modest current revenue and ongoing cash burn. For investors, the story hinges on whether the company can convert its growing validation and partner interest into scalable, reimbursed products fast enough to support the balance sheet and unlock the commercial opportunity across human and veterinary health.